Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hypnosis may offer Drug-Free relief for COPD anxiety and breathlessness

NCT ID NCT04868357

Symptom relief Sponsor: Centre Hospitalier de Bligny Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether learning self-hypnosis can help people with severe COPD manage anxiety and shortness of breath during pulmonary rehabilitation. 133 participants took part, with some learning hypnosis techniques in two group sessions. The goal was to see if hypnosis could reduce anxiety and improve breathing comfort, both during rehab and for three months after. If effective, it could provide a simple, complementary tool for symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
self-administered hypnosis (behavioral intervention)
What this could lead to
If it works, this could give COPD patients a simple, drug-free way to manage anxiety and breathlessness at home.
What could go wrong
This is a small, completed trial with 133 participants. Hypnosis may not work for everyone, and benefits might not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

133 people

The number who actually took part.

Started

Sep 2021

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged \> 30. * Affiliated to a Social Security scheme or beneficiary of such a scheme. * Absence of cognitive disease questioning the validity of patient reported outcomes * Ability to give free, informed consent. * Adult patients with severe COPD, dyspnea ; with distension. * Hospitalized at the CHB. * Predicted FEV1 and FEV/FVC percentages consistent with severe COPD according to GOLD standards. * Modified Research Council Questionnaire ≥2 * Exposure to tobbacco \>= 10 packs/yrs. Exclusion Criteria: * Pregnancy * Known severe cardiac insufficiency. * Known severe pulmonary arterial hypertension. * Evolutive-cancer diagnosis. * Significant cognitive impairment, hypercapnic encephalopathy or confusional syndrome. * Deafness. * Anemia ≤ 8g/dL. * Psychotic pathology.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder chronic obstructive pulmonary disease COPD, severe early onset Depression Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety COPD Dyspnea

Contacts and locations

Locations

  • Centre Hospitalier de Bligny

    Briis-sous-Forges, Briis-sous-Forges, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.